Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Vaccine Sales Jump 50 Percent In Q3

This article was originally published in The Pink Sheet Daily

Executive Summary

Performance of vaccines business helps offset slight decline in pharmaceuticals revenues, hard hit by Ambien IR generics.

You may also be interested in...

Sanofi’s Menactra Use Expanded To Children

Sanofi Pasteur’s meningococcal conjugate vaccine approved for use in children 2 years to 10 years old.

Court Rules Against Sanofi In Lovenox Patent Case Again; Second Round Of Appeals Likely

Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.

Menactra Supply Shortage Will Be Resolved By Fall, FDA Says

CDC recommends Sanofi Pasteur’s oral meningococcal disease vaccine Menomune as an “acceptable alternative” to the firm’s intramuscular vaccine.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts